BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 10701306)

  • 1. [Vasopeptidase inhibitors. Omapatrilat in hypertension and heart failure].
    Heinzl S
    Med Monatsschr Pharm; 2000 Feb; 23(2):38-41. PubMed ID: 10701306
    [No Abstract]   [Full Text] [Related]  

  • 2. Vasopeptidase inhibitors.
    Weber MA
    Lancet; 2001 Nov; 358(9292):1525-32. PubMed ID: 11705582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Omapatrilat.
    Drugs R D; 1999 Apr; 1(4):350-1. PubMed ID: 10566062
    [No Abstract]   [Full Text] [Related]  

  • 4. [Omapatrilat for treatment of heart failure].
    Yamazaki T
    Nihon Rinsho; 2007 May; 65 Suppl 5():173-5. PubMed ID: 17571381
    [No Abstract]   [Full Text] [Related]  

  • 5. [Omapatrilat--new drug for patients with hypertension and heart failure].
    Dzielska-Olczak M
    Pol Merkur Lekarski; 2005 Oct; 19(112):556-8. PubMed ID: 16379325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vasopeptidase inhibition: a new concept in blood pressure management.
    Burnett JC
    J Hypertens Suppl; 1999 Feb; 17(1):S37-43. PubMed ID: 10340842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Omapatrilat for the management of heart failure and hypertension.
    Husereau DR
    Issues Emerg Health Technol; 2001 Jun; (17):1-4. PubMed ID: 11776285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined neutral endopeptidase inhibitors.
    Cuculi F; Erne P
    Expert Opin Investig Drugs; 2011 Apr; 20(4):457-63. PubMed ID: 21323474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Omapatrilat.
    Armstrong PW; Lorell BH; Nissen S; Borer J
    Circulation; 2002 Aug; 106(6):e9011-2. PubMed ID: 12187916
    [No Abstract]   [Full Text] [Related]  

  • 10. Vasopeptidase inhibitors in heart failure.
    Dawson A; Struthers AD
    J Renin Angiotensin Aldosterone Syst; 2002 Sep; 3(3):156-9. PubMed ID: 12563565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of angiotensin-converting enzyme or vasopeptidase inhibition on ventricular size and function in patients with heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) echocardiographic study.
    Solomon SD; Skali H; Bourgoun M; Fang J; Ghali JK; Martelet M; Wojciechowski D; Ansmite B; Skards J; Laks T; Henry D; Packer M; Pfeffer MA;
    Am Heart J; 2005 Aug; 150(2):257-62. PubMed ID: 16086927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vasopeptidase inhibitors--concepts and evidence.
    Ruschitzka F; Corti R; Quaschning T; Hermann M; Lüscher TF
    Nephrol Dial Transplant; 2001 Aug; 16(8):1532-5. PubMed ID: 11477147
    [No Abstract]   [Full Text] [Related]  

  • 13. MDL 100240.
    Drugs R D; 1999 Apr; 1(4):348-9. PubMed ID: 10566061
    [No Abstract]   [Full Text] [Related]  

  • 14. Omapatrilat. Bristol-Myers Squibb.
    Tabrizchi R
    Curr Opin Investig Drugs; 2001 Oct; 2(10):1414-22. PubMed ID: 11890357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vasopeptidase inhibition in heart failure.
    van Veldhuisen DJ; van Gilst WH
    Lancet; 2000 Oct; 356(9240):1526. PubMed ID: 11081561
    [No Abstract]   [Full Text] [Related]  

  • 16. [Vasopeptidase inhibition: a new mechanism of action--a new antihypertensive drug].
    Waeber B
    Praxis (Bern 1994); 2000 Apr; 89(16):649-53. PubMed ID: 10823018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Omapatrilat reduces pulse pressure and proximal aortic stiffness in patients with systolic hypertension: results of the conduit hemodynamics of omapatrilat international research study.
    Mitchell GF; Izzo JL; Lacourcière Y; Ouellet JP; Neutel J; Qian C; Kerwin LJ; Block AJ; Pfeffer MA
    Circulation; 2002 Jun; 105(25):2955-61. PubMed ID: 12081987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review of vasopeptidase inhibitors: a new modality in the treatment of hypertension and chronic heart failure.
    Nathisuwan S; Talbert RL
    Pharmacotherapy; 2002 Jan; 22(1):27-42. PubMed ID: 11794428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamics and pharmacokinetics of omapatrilat in heart failure.
    Kostis JB; Klapholz M; Delaney C; Vesterqvist O; Cohen M; Manning JA; Jemal M; Kollia GD; Liao WC
    J Clin Pharmacol; 2001 Dec; 41(12):1280-90. PubMed ID: 11762555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent clinical trials with omapatrilat: new developments.
    Zanchi A; Maillard M; Burnier M
    Curr Hypertens Rep; 2003 Aug; 5(4):346-52. PubMed ID: 12844471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.